Detail page

Knowledge Web

Person

Thorsten Zenz (1970-)

Arzt

Name	Thorsten Zenz
Time	1970- (Date of birth and death)
Place	Essen (Geburtsort) Heidelberg (Wirkungsort) Zürich (Wirkungsort) Deutschland
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession)
Related	Klinikum Heidelberg Universitätsspital Zürich (2018-)
Further information	Habil. Fach Innere Medizin an der Univ. Ulm; Oberarzt, Zentrum für Innere Medizin, Medizinische Klinik der Universität Heidelberg; Leitender Arzt in der Klinik für Hämatologie am Zentrum für Hämatologie und Onkologie des Universitätsspitals Zürich
Record type	Person
GND-Identifier	114963738
Record ID	114963738
Involved in show all Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape Proteogenomics refines the molecular classification of chronic lymphocytic leukemia Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels Requirement for YAP1 signaling in myxoid liposarcoma Systematic investigation of disease- and genotype-specific vulnerabilities in primary blood cancer using high-throughput ex vivo drug screening SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets RAF-Inhibitoren Drug-perturbation-based stratification of blood cancer Haarzell-Leukämie Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing Stammzelltransplantationen bei hämatologischen Erkrankungen : Balance zwischen Wirkung und Nebenwirkung Verordnungsverhalten niedergelassener Ärzte bei der Therapie von Tumorschmerzen : eine dreijährige Untersuchung in 330 Praxen

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Thorsten Zenz (1970-)

Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

Requirement for YAP1 signaling in myxoid liposarcoma

Systematic investigation of disease- and genotype-specific vulnerabilities in primary blood cancer using high-throughput ex vivo drug screening

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia

Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets

RAF-Inhibitoren

Drug-perturbation-based stratification of blood cancer

Haarzell-Leukämie

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

Stammzelltransplantationen bei hämatologischen Erkrankungen : Balance zwischen Wirkung und Nebenwirkung

Verordnungsverhalten niedergelassener Ärzte bei der Therapie von Tumorschmerzen : eine dreijährige Untersuchung in 330 Praxen